LONDON, July 9 British pharmaceutical company
AstraZeneca has agreed its first research partnerships
in Cambridge for cancer treatments ahead of its relocation to
the university city by 2016.
The firm said it would work on three oncology projects with
Cancer Research UK and the University of Cambridge's department
of oncology at Addenbrooke's Hospital, located next to the site
for its new research centre and headquarters.
The projects include using blood tests to monitor tumours
instead of biopsies, potential drugs for prostate cancer, and
new approaches for pancreatic cancer, which has a very poor
prognosis and few treatments available, the company said on
AstraZeneca's move to Cambridge is the centrepiece of $2.3
billion restructuring plan unveiled by new chief executive
Pascal Soriot in March. It confirmed last month that it would be
based at the Cambridge Biomedical Campus.
Susan Galbraith, head of AstraZeneca's Oncology Innovative
Medicines Unit, said it was fitting that the first
collaborations since announcing the move were in cancer because
its Cambridge facility will become its largest centre for